News

Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations Significantly

Biotechnology company Moderna (NASDAQ:MRNA) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other hand, the company’s full-year revenue guidance of $2 billion at the midpoint came in 9.8% below analysts’ estimates. Its GAAP loss of $2.91 per share was 6.7% below analysts’ consensus estimates.

Cheap cigarettes will continue taking US market share, tobacco firm JTI predicts

Japan Tobacco International expects a shift towards cheaper cigarette brands in the United States to reach more than 40% of the market by 2027, its finance chief told Reuters. U.S. smokers have been swapping out brands such as Altria's Marlboro and British American Tobacco's (BAT) Newport, which have been raising prices for years, for less expensive brands as high inflation and interest rates stretch their wallets. BAT's U.S. cigarette volumes fell 10.1% last year in part due to this shift, it reported on Thursday, while Altria has also been losing market share.

Wall St subdued as markets await tariff details

Wall Street's main indexes were muted on Friday, as investors awaited more clarity on U.S. President Donald Trump's reciprocal tariff plans after robust gains in the last sessions, with all three benchmarks set for weekly gains. Trump tasked his economics team on Thursday with devising plans for reciprocal tariffs on every country taxing U.S. imports, though the directive stopped short of imposing fresh tariffs. Howard Lutnick, Trump's pick for commerce secretary, said the administration would address each affected country one by one and said studies on the issue would be completed by April 1.